Long-term stability of cancer biomarkers in human serum: Biomarkers of oxidative stress and redox status, homocysteine, CRP and the enzymes ALT and GGT

Biomarkers in Medicine

Volumn 9, Issue 5, 2015, Pages 425-432

  Jansen, Eugène ^a   Beekhof, Piet ^a   Viezeliene, Dale ^b   Muzakova, Vladimira ^c   Skalicky, Jiri ^d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^c UNIVERSITY OF PARDUBICE   (Czech Republic)

^d Pardubice Regional Hospital   (Czech Republic)

Author keywords

Alanine aminotransferase; C reactive protein; Cancer biomarkers; Homocysteine; Hydroperoxides; Stability; Storage; Total thiols; glutamyltransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HOMOCYSTEINE; REACTIVE OXYGEN METABOLITE; THIOL; TUMOR MARKER;

ANALYTICAL PARAMETERS; ARTICLE; BLOOD STORAGE; CANCER RESEARCH; CONTROLLED STUDY; ENZYME BLOOD LEVEL; HUMAN; MOLECULAR DYNAMICS; MOLECULAR STABILITY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RELIABILITY; TEMPERATURE DEPENDENCE; TIME SERIES ANALYSIS; TOTAL THIOL LEVEL; BLOOD; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ALANINE TRANSAMINASE; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; GAMMA-GLUTAMYLTRANSFERASE; HOMOCYSTEINE; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84929583778     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.14     Document Type: Article

References (50)

1. Lippi G, Chance JJ, Church S et al. Preanalytical quality improvement: from dream to reality. Clin. Chem. Lab. Med. 49, 1113-1126 (2011).
2. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mut. Res. 567, 1-61 (2004).
3. Leufkens AM, van Duijnhoven FJB, Woudt SHS et al. Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case-control study in the EPIC study. Am. J. Epidemiol. 175, 653-663 (2012). •• This is the first paper that described the significant and positive relation between oxidative stress and cancer in an epidemiological setting.
4. Aleksandrova K, Drogan D, Boeing H et al. Adiposity, mediating biomarkers and risk of colon cancer in the European Prospective Investigation into Cancer and Nutrition Study. Int. J. Cancer 134, 612-621 (2014). •• A prospective study using biomarkers to characterize adiposity and the risk of colon cancer in a very elegant way.
5. Aleksandrova K, Jenab M, Bueno-de-Mesquita HB et al. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur. J. Epidemiol. 29, 261-275 (2014). • In this paper the connection between several biomarkers of oxidative stress and inflammation was established.
6. Schöttker B, Saum KU, Jansen EHJ M et al. Metabolic, inflammatory and oxidative stress markers of (multi-) morbidity at older age. A large population-based cohort study. J. Gerontol. doi:10.1093/gerona/glu111 (2014) (In Press). •• This is the first paper in which both biomarkers of oxidative stress (ROM) and redox status (TTL) have been applied in morbidity studies at a large scale.
7. Vassalle C, Bianchi S, Battaglia D, Landi P, Bianchi F, Carpeggiani C. Elevated levels of oxidative stress as a prognostic predictor of major adverse cardiovascular events in patients with coronary artery disease. J. Atheroscler. Thromb. 19, 712-717 (2012). • This study used the biomarkers for oxidative stress (ROM) for the first time in relation to cardiovascular complications.
8. Vassalle C, Bianchi S, Bianchi F, Landi P, Battaglia D, Carpeggiani C. Oxidative stress as a predictor of cardiovascular events in coronary artery disease patients. Clin. Chem. Lab. Med. 50, 1463-1468 (2012).
9. Cornelli U, Terranova R, Luca S, Cornelli M, Alberti A. Bioavailability of some food supplementations in men and women using the d-ROMs test as a marker of oxidative stress. J. Nutr. 131, 3208-3211 (2001).
10. Jansen EHJM, Beekhof PK, Cremers JWJM, Viezeliene D, Muzakova V, Skalicky J. Short-term stability of biomarkers of oxidative stress and antioxidant status in human serum. ISRN Biomarkers doi.org/10.1155/2013/316528 (2013).
11. Lamele L, Fiocchi R, Vernocchi A. Evaluation of an automated spectrophotometric assay for reactive oxygen metabolites in serum. Clin. Chem. Lab. Med. 40, 673-676 (2002).
12. Da Costa CM, Dos Santos RCC, Lima ES. A simple automated procedure for thiol measurement in human serum samples. J. Bras. Patol. Med. Lab. 42, 345-350 (2006).
13. Ellman GL. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70-77 (1959).
14. Hu ML. Measurement of protein thiol groups and glutathionein plasma. Meth. Enzymol. 233, 380-385 (1984).
15. De Flora S, Izzotti A, D'Agostini F, Cesarone CF. Oxidants and antioxidants: pathophysiologic determinants and therapeutic agents. Am. J. Med. 91, S122-S130 (1991).
16. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett. 208, 143-153 (2004). • This paper was one of the first studies to recognize the value of the redox system as characterized by the biomarkers representing the total thiols in serum.
17. Fiskerstrand T, Refsum H, Kvalhehn G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin. Chem. 39, 263-271 (1993).
18. Salazar JF, Herbeth B, Siest G, Leroy P. Stability of blood homocysteine and other thiols: EDTA or acidic citrate? Clin. Chem. 45, 2016-2019 (1999).
19. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J. Inherit. Metab. Dis. 34, 75-81 (2011).
20. Huanga T, Chena Y, Yanga B, Yanga J, Wahlqvist ML, Li D. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin. Nutr. 31, 448-454 (2012).
21. Obersby D, Chappell DC, Tsiami AA. Plasma total homocysteine and its relationship with cardiovascular disease. J. Nutr. Therap. 4, 182-193 (2013).
22. Clarke R, Halsey J, Bennett D, Lewington S. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J. Inherit. Metab. Dis. 34, 83-91 (2011).
23. Clarke R, Halsey J, Lewington S et al. B-vitamin treatment trialists' collaboration. Effects of lowering homocysteine levels with b vitamins on cardiovascular disease, cancer, and cause-specific mortality meta-analysis of 8 randomized trials involving 37485 individuals. Arch. Intern. Med. 170, 1622-1631 (2010).
24. Zhang SM, Willett WC, Selhub J et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J. Natl Cancer Inst. 95, 373-380 (2003).
25. Kato I, Dnistrian AM, Schwartz M et al. Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br. J. Cancer 79, 1917-1921 (1999).
26. Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int. J. Cancer 113, 819-824 (2005).
27. Chou YC, Lee MS, Wu MH et al. Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case-control study in Taiwan. Breast Cancer Res. Treat. 101, 199-205 (2007).
28. Zylberstein DE, Bengtsson C, Björkelund C et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease. 24-year follow-up of the population study of women in Gothenburg. Circulation 109, 601-606 (2004).
29. Cavalca V, Cighetti G, Bamonti F et al. Oxidative stress and homocysteine in coronary artery disease. Clin. Chem. 47, 887-892 (2001).
30. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106, 9-19 (1994).
31. Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B. Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone 51, 376-382 (2012).
32. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Heart 289, 2649-2656 (2005).
33. Hill DM, Johnson LJ, Burns PJ, Neale AM, Harmening DM, Kenney AC. Effects of temperature on stability of blood homocysteine in collection tubes containing 3-deazaadenosine. Clin. Chem. 48, 2017-2022 (2002).
34. Israelsson B, Brattstrom L, Refsum H. Homocysteine in frozen plasma samples: a short cut to establish hyperhomocysteinaemias a risk factor for arteriosclerosis? Scand. J. Lab. Invest. 53, 465-469 (1993).
35. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit. Rev. Clin. Lab. Sci. 48, 155-170 (2011).
36. Ko YJ, Kwon YM, Kim KH et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol. Biomarkers Prev. 21, 2076-2086 (2012).
37. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int. J. Cancer 123, 1133-1140 (2008).
38. Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin. Vaccine Immunol. 10, 652-657 (2003).
39. Brindle E, Fujita M, Shofer J, O'Connor KA. Serum, plasma, and dried blood spot high sensitivity C-reactive protein enzyme immunoassay for population research. J. Immunol. Meth. 362, 112-120 (2010).
40. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb. Haemost. 86, 1495-1500 (2001).
41. Strasak AM, Rapp K, Brant LJ et al. Association of γ-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res. 68, 3970-3977 (2008).
42. Pompella A, Corti A, Paolicchi A, Giommarelli C, Zunino F. Glutamyltransferase, redox regulation and cancer drug resistance. Curr. Opin. Pharmacol. 7, 360-366 (2007).
43. Strasak AM, Pfeiffer RM, Klenk J et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. Int. J. Cancer 123, 1902-1906 (2008).
44. Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic. Res. 38, 535-539 (2004).
45. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR, Lee DH. Is serum γ-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic. Biol. Med. 37, 1018-1023 (2004).
46. Tarao K, Rino Y, Ohkawa S et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 86, 589-595 (1999).
47. Yamada J, Tomiyama H, Yambe M et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 189, 198-205 (2006).
48. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and γ-glutamyltransferase and mortality in the United States population. Eur. J. Gastroenterol. Hepatol. 21, 487-490 (2009).
49. Jackson C, Best N, PElliott PE. UK Biobank Pilot Study: stability of haematological and clinical chemistry analytes. Int. J. Epidemiol. 37, 16-22 (2008).
50. Tanner M, Kent N, Smith B, Fletcher S, Lewer M. Stability of common biochemical analytes in serum gel tubes subjected to various storage temperatures and times pre-centrifugation. Ann. Clin. Biochem. 45, 375-379 (2008).